Levitee Labs Announces Philip Van Den Berg to Join as Interim CEO and the Board of Directors and Close First Tranche of Private Placement for $1.5 Million
February 01, 2022 16:05 ET
|
Levitee Labs Inc.
VANCOUVER, British Columbia, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the "Company" or "Levitee”) is pleased to announce the Company has appointed...
Levitee Labs Announces Non-Brokered Private Placement of up to $3,000,000
January 18, 2022 16:15 ET
|
Levitee Labs Inc.
Offering is priced at $0.20 per offered unit, with a full warrant at $0.40 for 24 monthsProceeds to be used for organic and inorganic growth initiatives and refocusing the company on clinical...
Levitee Labs Signs Retail Distribution Agreement with Body Energy Club for MONKE Nutraceuticals
January 12, 2022 08:00 ET
|
Levitee Labs Inc.
In business for 20 years, Body Energy Club is the leading health supplement and vitamin retailer in Western Canada, with additional locations established in Hollywood, California in 2017Levitee...
Levitee Labs Partners with Canntab Therapeutics to Provide Alternatives to Opioids
January 10, 2022 08:00 ET
|
Levitee Labs Inc.
The agreement is anticipated to contribute to correcting the opioid crisis in Canada and serve as a foundation for both companies to potentially expand into new verticals in the futureLevitee Labs and...
CORRECTION - Levitee Labs Announces Medical Advisory Board
January 06, 2022 12:32 ET
|
Levitee Labs Inc.
VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- In a press release issued earlier today under the same headline by Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7), please be...
Levitee Labs Announces Medical Advisory Board
January 06, 2022 08:00 ET
|
Levitee Labs Inc.
Newly appointed Medical Advisory Board brings decades of relevant experience in addiction, mental health, drug development, compounding, chronic pain, policy, neurology, and psychedelic medicine to...
Levitee Labs Announces Strategic Partnership with LiveRx Research Group to Provide Equitable Access to Hepatitis C Care throughout Alberta, Canada
December 20, 2021 08:00 ET
|
Levitee Labs Inc.
Treatment for Hepatitis C Virus (HCV) is effective in over 95% of infected patients, yet remains disproportionately unavailable to certain patient groups across Canada.Levitee Clinics and Levitee...
Levitee Labs Appoints Noha ElSayed as Executive Director for Levitee Clinics and Levitee Pharmacies in the Alberta Region
November 15, 2021 08:00 ET
|
Levitee Labs Inc.
Levitee adds Noha ElSayed, an expert in compounding and pharmacy operations, to the Levitee Clinics and Levitee Pharmacies management teamMrs. ElSayed has over 20 years of experience as a pharmacist...
Levitee Labs Signs Letter of Intent to Acquire a Chain of Specialty Addiction Pharmacies Located in British Columbia
November 10, 2021 08:00 ET
|
Levitee Labs Inc.
Signed LOI to acquire 100% interest in chain of specialty addiction pharmacies in Vancouver, BCAcquisition price of $4.0 million based upon approximately 4.7x trailing 6 months annualized EBITDA of...
Levitee Labs Publishes First Combined Revenue Figures for September 2021 and October 2021
November 08, 2021 16:00 ET
|
Levitee Labs Inc.
Levitee Labs achieves combined September 2021 and October 2021 revenues of $1,553,728Consistent revenue growth and acquisitions across core divisions of the company, including Levitee Clinics, Levitee...